Despite the inherent limitations of the studies reviewed, there is cautious optimism that SGLT2 inhibitors, recognized for their potent cardiorenal protective effects, will confer significant therapeutic benefits to SLE patients, potentially enhancing immune regulation alongside standard immunosuppressive treatments. Here, SLC5A2 is linked to systemic lupus erythematosus.